Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (-)-[18F]Flubatine in humans

Nuclear Medicine and Biology

Volumn 41, Issue 6, 2014, Pages 489-494

  Patt, Marianne ^a   Becker, Georg A ^a   Grossmann, Udo ^a   Habermann, Bernd ^a   Schildan, Andreas ^a   Wilke, Stephan ^a   Deuther Conrad, Winnie ^b   Graef, Susanne ^a   Fischer, Steffen ^b   Smits, René ^c   Hoepping, Alexander ^c   Wagenknecht, Gudrun ^d   Steinbach, Jörg ^b   Gertz, Hermann Josef ^a   Hesse, Swen ^a   Schönknecht, Peter ^a   Brust, Peter ^b   Sabri, Osama ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c ABX Advanced Biochemical Compounds GmbH   (Germany)

^d FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Clinical trial; Flubatine; Fluorine 18; Metabolism; PET; Plasma protein binding

Indexed keywords

FLUBATINE F 18; TRACER; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; FLUORONORCHLOROEPIBATIDINE; FUSED HETEROCYCLIC RINGS; PLASMA PROTEIN; PROTEIN BINDING;

ARTICLE; BLOOD; BLOOD COMPONENT; BLOOD VOLUME; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG METABOLISM; EX VIVO STUDY; GAMMA RADIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PLASMA; PLASMA PROTEIN BINDING; RADIATION MEASUREMENT; RADIOACTIVITY; SAMPLE; ULTRACENTRIFUGATION; KINETICS; METABOLISM;

BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PROTEINS; HUMANS; KINETICS; PROTEIN BINDING; RADIOACTIVE TRACERS;

EID: 84901275693     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.03.018     Document Type: Article

References (17)

1. Becker G., Wilke S., Schönknecht P., Patt M., Luthardt J., Hesse S., et al. PET quantification of (-)-[18F]-flubatine binding to nicotinic alpha4beta2 acetylcholine receptors in human brains. J Cereb Blood Flow Metab 2012, 32:S172.
2. Sabri O., Wilke S., Graef S., Becker G., Hesse S., Schönknecht P., et al. PET imaging of cerebral nicotinic acetylcholine receptors (nAChRs) in early Alzheimer's disease assessed with the new radioligand (-)-[18F]-norchloro-fluoro-homoepibatidine ([18F]Flubatine). J Cereb Blood Flow Metab 2012, 32:S55.
3. 2 nicotinic acetylcholine receptors. Appl Radiat Isot 2013, 74:128-136.
4. Deuther-Conrad W., Patt J.T., Feuerbach D., Wegner F., Brust P., Steinbach J. Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Farmaco 2004, 59:785-792.
5. Meyer P.M., Strecker K., Kendziorra K., Becker G., Hesse S., Woelpl D., et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009, 66:866-877.
6. Hillmer A.T., Wooten D.W., Slesarev M.S., Ahlers E.O., Barnhart T.E., Murali D., et al. PET imaging of alpha4beta2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. J Nucl Med 2012, 53:1471-1480.
7. Bohnen N.I., Frey K.A. The role of positron emission tomography imaging in movement disorders. Neuroimaging Clin N Am 2003, 13:791-803.
8. Horti A.G., Gao Y., Kuwabara H., Dannals R.F. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci 2010, 86:575-584.
9. Kendziorra K., Wolf H., Meyer P.M., Barthel H., Hesse S., Becker G.A., et al. Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2011, 38:515-525.
10. Sabri O., Kendziorra K., Wolf H., Gertz H.J., Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2008, 35(Suppl 1):S30-S45.
11. Sabri O, Graef S, Wilke S, Hesse S, Becker GAF, Patt M, et al. Cerebral α4β2-nicotinic receptors in early Alzheimer's disease: first in-man study using the new specific PET ligand (-)-[18F]Flubatine. [in press].
12. Laruelle M., Slifstein M., Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 2002, 27:287-299.
13. 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med 2013, 54:723-731.
14. Smits R., Fischer S., Hiller A., Deuther-Conrad W., Wenzel B., Patt M., et al. Synthesis and biological evaluation of both enantiomers of [(18)F]flubatine, promising radiotracers with fast kinetics for the imaging of alpha4beta2-nicotinic acetylcholine receptors. Bioorg Med Chem 2014, 22:804-812.
15. Patt M., Schildan A., Habermann B., Fischer S., Hiller A., Deuther-Conrad W., et al. Fully automated radiosynthesis of both enantiomers of [18F]Flubatine under GMP conditions for human application. Appl Radiat Isot 2013, 80:7-11.
16. Sorger D., Becker G.A., Hauber K., Schildan A., Patt M., Birkenmeier G., et al. Binding properties of the cerebral alpha4beta2 nicotinic acetylcholine receptor ligand 2-[18F]fluoro-A-85380 to plasma proteins. Nucl Med Biol 2006, 33:899-906.
17. 18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanal Nucl Chem 2010, 284:557-562.